Skip to main content
. 2018;19(2):387–393. doi: 10.22034/APJCP.2018.19.2.387

Figure 4.

Figure 4

Immunohistochemical Examination of VEGF Expression in Liver Tissues of the Studied Groups. (A)Negative control, (B) HCC untreated, (C) HCC + Doxorubicin, (D) HCC + Ellagic acid

HHS Vulnerability Disclosure